1. Optimization of a deprescribing case treatment​​​

​

Examination and optimization of various treatment options by selection of individual drugs or complete drug classes for a deprescribing patient's conditions (Diabetes mellitus type 2, Chronic heart failure/ myocardial infarction prevention, Insomnia, Depressive disorder, Upper GI bleeding/ peptic ulcer, Constipation, Increased urinary frequency and vitamin D deficiency. The tool selects the treatment drugs from the selected classes with minimal adverse drug effects and interactions. Particularly, the tool minimizes the counts of (i) adverse drug reactions (ADR), (ii) critical and other drug-drug interactions (DDI), (iii) drug condition interactions (DCI), (iv) Beers drug warnings, (v) Beers DDI warnings and Beers drug-condition warnings.

​​​

​​

2. Finding optimized treatment for 12 frequent diseases

​​

This application finds polypharmacy treatments with minimal drug interactions for one or more of the following diseases: diabetes mellitus type 2 (DMT2), Heart failure (HF), Hypertensive disorder (HT), Atherosclerotic cardiovascular disease (ASCVD), Hypercholesterolemia (HC), Rheumatoid arthritis (ARTH), Depressive disorder (DEP), Anxiety disorder (ANX), Chronic obstructive pulmonary disease (COPD), Diabetic renal disease (DRD), Chronic kidney disease (CKD), and Obesity (OB). 

​

3. Finding optimized treatment for diabetes mellitus type 2, ASCVD and heart disease

​

This application finds polypharmacy treatments for DMT2 (Diabetes mellitus type 2), HF  (Heart failure)  and ASCVD  (Arteriosclerotic cardiovascular disease).  Drug Combinations for DMT2:  Three drugs from different classes; HF: One ACEi or ARB drug, one BB drug and one drug from MRA, LD, TD, or PSD classes; ASCVD: One STAT drug and one drug from BAS, CAI, FAA, or PCSK9i classes. A complete analysis of all treatments is provided in the article:  https://doi.org/10.1016/j.imu.2023.101267.

​